Aptorum Group Ltd(APM) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -0.35 | Insider Own | 34.85% | Shs Outstand | 6.3M | Perf Week | -10.49% |
| Market Cap | 0.01B | Forward P/E | - | EPS next Y | - | Insider Trans | - | Shs Float | 5.3M | Perf Month | -16.92% |
| Enterprise Value | -0.00B | PEG | - | EPS next Q | - | Inst Own | 1.92% | Short Float | 1.18% | Perf Quarter | -22.22% |
| Income | -0.00B | P/S | - | EPS this Y | - | Inst Trans | 0.15% | Short Ratio | 0.44 | Perf Half Y | -33.96% |
| Sales | 0.00B | P/B | 0.25 | EPS next 5Y | - | ROA | -11.54% | Short Interest | 0.06M | Perf YTD | -33.96% |
| Book/sh | 2.84 | P/C | 1.65 | EPS past 3/5Y | 59.28% - | ROE | -9.02% | 52W High | -84.34% ($4.47) | Perf Year | -64.47% |
| Cash/sh | 0.42 | P/FCF | - | Sales past 3/5Y | - | ROIC | -8.94% | 52W Low | 14.72% ($0.61) | Perf 3Y | -69.83% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -1979.68% | Gross Margin | - | Volatility(W/M) | 10.99% 6.95% | Perf 5Y | -97.52% |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 0.08 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 0.78 | EPS Q/Q | - | Profit Margin | - | RSI (14) | 34.68 | Recom | - |
| Dividend Gr. 3/5Y | - | Current Ratio | 0.78 | Sales Q/Q | - | SMA20 | -11.36% ($0.79) | Beta | 0.2 | Target Price | $230 |
| Payout | - | Debt/Eq | 0.15 | Earnings | - | SMA50 | -18.53% ($0.86) | Rel Volume | 1.17 | Prev Close | $0.69 |
| Employees | 2 | LT Debt/Eq | 0 | EPS/Sales Surpr. | - | SMA200 | -34.94% ($1.08) | Avg Volume(3M) | 0.14M | Price | $0.7 |
| IPO | 2018/12/18 | Option/Short | No/Yes | Trades | 2564 | Volume | 165,024 | Change | 1.1% |
🧪 (Aptorum Group) is a clinical-stage biopharmaceutical micro-cap holding company headquartered in Hong Kong. Through drug repurposing, it simultaneously develops oncology drugs, antibiotics, and diagnostic platforms, with its core pipeline consisting of the neuroblastoma oncology candidate SACT-1, the Staphylococcus aureus antibiotic ALS-4, and the liquid biopsy rapid pathogen diagnostics RPIDD.
Over the past 1 year, on the lower side
84% below its 1-year high.
Traded about as much as usual. That is 117% of its average volume.
APM has weak earning power
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -97.5%. The S&P 500 did +64% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Institutions barely hold it
Institutions hold 1.9%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #537 of 598 in the industry
Based on market cap of $6M.
FAQ
What kind of company is APM?
APM belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of APM?
The market cap of APM is approximately $6M, ranking 5,655 within its sector.
What is the 52-week high and low for APM?
APM has recorded a 52-week high of $4.47 and a low of $0.61.
